SymBio Pharmaceuticals

SymBio Pharmaceuticals Limited

Company highlights

The largest holder on the register is 吉田文紀, at 2.8%.

Key figures

Period Jan 2025 to Dec 2025ConsolidatedJapanese GAAP

RevenueDisclosed ¥1.3B

Operating marginCalculated -339.6%

Net assets to total assetsCalculated 32.9%

Company profile

Securities code 4582 / EDINET code E24682 / Pharmaceuticals / Fiscal year end end of December

港区虎ノ門四丁目１番２８号／Capital stock ¥17,952 million
Address, capital stock, fiscal year end and industry: the FSA’s EDINET code list.

Company details

吉田文紀 Representative

1 Consolidated subsidiaries

Tables scroll sideways

Disclosed data

Source: Annual Securities Report (Jan 2025 to Dec 2025) · filed 2026-03-24

Profitability ★☆☆☆☆position among all companies -339.6%

Growth (revenue, 3-year average) ★☆☆☆☆position among all companies -49.3%

Capital efficiency Could not be retrieved

Business activities and revenue composition

Breakdown by business: not published

Revenue and profit

SymBio Pharmaceuticals

Period Jan 2025 to Dec 2025Source Annual securities reports

Amounts by account

Group	Account	Amount	Consolidated / Non-consolidated
Selling, general and administrative expenses	Research and development expenses	¥3.3 billion	Consolidated
	Promotion expenses	¥0.5 billion	Consolidated
	Payrolls and allowances	¥0.5 billion	Consolidated
	Directors' compensations	¥0.2 billion	Consolidated
	Fee expenses	¥60.50 million	Parent only
	Retirement benefit expenses	¥0.64 million	Consolidated
Profit by stage	Net income	¥-4.8 billion	Consolidated
	Ordinary income	¥-4.6 billion	Consolidated
	Operating income	¥-4.4 billion	Consolidated
	Gross profit (loss)	¥0.9 billion	Consolidated

SymBio Pharmaceuticals

Selling, general and administrative expenses

Period Jan 2025 to Dec 2025Source Annual securities reports

Research and development expenses　¥3.3 billion
Promotion expenses　¥0.5 billion
Payrolls and allowances　¥0.5 billion
Directors' compensations　¥0.2 billion
Fee expenses　¥0.1 billion
Retirement benefit expenses　¥0.0 billion
Other (not itemized)　¥0.8 billion

Performance, financial position and capital allocation

Finance

32.9% Net assets to total assets Industry median 69.7% FY ending 12/2025 · consolidated / calculated

-123.5% Return on assets (ROA)

¥15.54 Net assets per share

¥-4.7 billion Free cash flow

¥3.9 billion Total assets

Capital allocation

-8.7% Increase in working capital ★☆☆☆☆ position among all companies FY ending 12/2025 · consolidated / calculated

Long-term changes in performance

Period 2012 to 2025Disclosed

Revenue ×0.67 from 2012 to 2025

SymBio Pharmaceuticals

Long-term revenue, profit and asset trends

Period 2012 to 2025Source Annual securities reportsDisclosed

Mark on the chartNo markHighest in the period shownLowest in the period shown

SymBio Pharmaceuticals

Recent performance trends

Source Annual securities reports

Year-on-year comparison

Period 2012 to 2025Disclosed

Item	2021	2022	2023	2024	2025
Net sales	¥8.3B	¥10.0B	¥5.6B	¥2.5B	¥1.3B
Year on year (%)	+176.4%◆	comparison basis not confirmed	-44.1%◆	-56.1%◆	-46.7%◆
Ordinary income (loss)	¥1.0B	¥2.0B	-¥0.7B	-¥3.7B	-¥4.6B
Change from prior year	loss to profit◆	comparison basis not confirmed	profit to loss◆	5.01x	1.26x
Ordinary income (loss) as a share of Net sales	12.1%	20.0%	-13.2%	-150.4%	-355.4%
Change (percentage points)	+166.7 points◆	comparison basis not confirmed	-33.2 points◆	-137.2 points◆	-205.0 points◆

Fiscal periods marked for changes

Earlier fiscal periods (8)

2013Net sales year on year -21.6%, Ordinary income (loss) as a share of revenue -16.1 points
2014Net sales year on year +27.6%, Ordinary income (loss) as a share of revenue +47.7 points
2015Ordinary income (loss) as a share of revenue -79.3 points
2016Net sales year on year +22.5%, Ordinary income (loss) as a share of revenue +38.2 points
2017Net sales year on year +45.4%, Ordinary income (loss) as a share of revenue -17.6 points
2018Ordinary income (loss) as a share of revenue +43.8 points
2019Net sales year on year -26.0%, Ordinary income (loss) as a share of revenue -82.6 points
2021Net sales year on year +176.4%, Ordinary income (loss) as a share of revenue +166.7 points, Ordinary income (loss) loss to profit

2023Net sales year on year -44.1%, Ordinary income (loss) as a share of revenue -33.2 points, Ordinary income (loss) profit to loss
2024Net sales year on year -56.1%, Ordinary income (loss) as a share of revenue -137.2 points
2025Net sales year on year -46.7%, Ordinary income (loss) as a share of revenue -205.0 points

SymBio Pharmaceuticals

Earnings and net assets per share over time

Unit yenSource Annual securities reports

Consolidated indicators (15 items)

Item	4 years ago	3 years ago	2 years ago	Last year	This year
Net sales	Could not be retrieved	¥10.0 billion	¥5.6 billion	¥2.5 billion	¥1.3 billion
Ordinary income (loss)	Could not be retrieved	¥2.0 billion	¥-0.7 billion	¥-3.7 billion	¥-4.6 billion
Net income (loss) attributable to owners of parent	Could not be retrieved	¥1.2 billion	¥-2.0 billion	¥-3.8 billion	¥-4.8 billion
Comprehensive income	Could not be retrieved	¥1.2 billion	¥-2.0 billion	¥-3.8 billion	¥-4.8 billion
Net assets	Could not be retrieved	¥8.5 billion	¥7.2 billion	¥4.2 billion	¥1.3 billion
Total assets	Could not be retrieved	¥10.4 billion	¥8.2 billion	¥5.0 billion	¥3.9 billion
Net assets per share	Could not be retrieved	204.83 yen	164.32 yen	84.66 yen	15.54 yen
Basic earnings (loss) per share	Could not be retrieved	30.2 yen	-49.19 yen	-85 yen	-95.12 yen
Diluted earnings per share	Could not be retrieved	29.77 yen	Could not be retrieved	Could not be retrieved	Could not be retrieved
Equity-to-asset ratio	Could not be retrieved	77.6%	84.9%	78.1%	23.9%
Return on equity	Could not be retrieved	14.6%	Could not be retrieved	Could not be retrieved	Could not be retrieved
Net cash provided by (used in) operating activities	Could not be retrieved	¥1.6 billion	¥-0.2 billion	¥-3.4 billion	¥-4.6 billion
Net cash provided by (used in) investing activities	Could not be retrieved	¥-47.13 million	¥-0.4 billion	¥-3.96 million	¥-75.92 million
Net cash provided by (used in) financing activities	Could not be retrieved	¥0.6 billion	¥0.7 billion	¥0.7 billion	¥3.6 billion
Cash and cash equivalents	Could not be retrieved	¥6.3 billion	¥6.5 billion	¥4.0 billion	¥2.9 billion

Parent only indicators (16 items)

Item	4 years ago	3 years ago	2 years ago	Last year	This year
Net sales	¥8.3 billion	¥10.0 billion	¥5.6 billion	¥2.5 billion	¥1.3 billion
Ordinary income (loss)	¥1.0 billion	¥2.0 billion	¥-0.8 billion	¥-3.8 billion	¥-4.8 billion
Net income (loss)	¥2.0 billion	¥1.2 billion	¥-2.0 billion	¥-3.9 billion	¥-4.9 billion
Capital stock	¥17.2 billion	¥17.5 billion	¥18.0 billion	¥18.3 billion	¥19.2 billion
Total number of issued shares (common stock)	38,457,206 shares	39,603,606 shares	42,278,081 shares	45,928,856 shares	59,567,080 shares
Net assets	¥6.7 billion	¥8.5 billion	¥7.2 billion	¥4.1 billion	¥1.0 billion
Total assets	¥8.5 billion	¥10.4 billion	¥8.2 billion	¥4.7 billion	¥3.6 billion
Net assets per share	162.26 yen	204.95 yen	164.02 yen	82.12 yen	11.38 yen
Basic earnings (loss) per share	53.04 yen	30.37 yen	-49.79 yen	-87 yen	-97.62 yen
Diluted earnings per share	52.32 yen	29.95 yen	Could not be retrieved	Could not be retrieved	Could not be retrieved
Equity-to-asset ratio	73.7%	77.8%	84.6%	79.7%	19.0%
Return on equity	39.6%	16.6%	Could not be retrieved	Could not be retrieved	Could not be retrieved
Net cash provided by (used in) operating activities	¥0.1 billion	Could not be retrieved	Could not be retrieved	Could not be retrieved	Could not be retrieved
Net cash provided by (used in) investing activities	¥-70.85 million	Could not be retrieved	Could not be retrieved	Could not be retrieved	Could not be retrieved
Net cash provided by (used in) financing activities	¥-71.92 million	Could not be retrieved	Could not be retrieved	Could not be retrieved	Could not be retrieved
Cash and cash equivalents	¥3.9 billion	Could not be retrieved	Could not be retrieved	Could not be retrieved	Could not be retrieved

Shareholder composition

As of 2025-12-31Disclosed

Share ownership by holder category

30,133 Shareholders

5.53% Foreign holders (total) Industry median 9.03%

85.27% Individuals and others Industry median 55.96%

SymBio Pharmaceuticals

Unit %Source Annual securities reports

Financial institutions0.53%
Securities firms7.40%
Other corporations1.26%
Foreign holders (institutions)4.28%
Foreign holders (individuals)1.25%
Individuals and others85.27%

Major shareholders

Rank	Shareholder	Shareholding ratio	Shares held
1	吉田文紀	2.83%	1,684,200
2	楽天証券株式会社共有口	2.38%	1,414,000
3	株式会社SBI証券	2.33%	1,384,480
4	MORGAN STANLEY ＆ CO. LLC（常任代理人モルガン・スタンレーMUFG証券株式会社）	1.6%	951,028
5	JPモルガン証券株式会社	0.91%	542,472
6	STATE STREET BANK AND TRUST COMPANY 510643（常任代理人株式会社みずほ銀行決済営業部）	0.86%	512,000
7	陳元	0.78%	466,800
8	村山信也	0.68%	402,200
9	木下みどり	0.56%	336,000
10	日本証券金融株式会社	0.53%	313,900

Research and development expenses and capital expenditure

Source: R&D and capital expenditure sections, annual securities reports · 3 years (2020 to 2025)Disclosed

¥3.3 billion Research and development 252.2% of revenue (industry median 14.7%)

Not disclosed Capital expenditure

Fiscal year	Research and development	Capital expenditure
FY ending 12/2025	¥3.3 billion	Could not be retrieved
FY ending 12/2024	¥3.4 billion	Could not be retrieved
FY ending 12/2020	¥2.3 billion	¥0.1 billion

Revenue scale in the same industry

SymBio Pharmaceuticals

Source Annual securities reports of each company

Pharmaceuticals: 68 companies · revenue · largest first・each company’s latest fiscal year・consolidated (parent-only where no consolidated figures)・Disclosed

1 Takeda PharmaceuticalFY Mar 2026 ¥4.5T
2 OtsukaFY Dec 2025 ¥2.5T
3 Astellas PharmaFY Mar 2026 ¥2.1T
… 43 companies
47 ＨｅａｒｔｓｅｅｄFY Dec 2025 ¥3.0B
48 StemCell InstituteFY Mar 2026 ¥2.8B
49 SymBio PharmaceuticalsThis companyFY Dec 2025 ¥1.3B
50 Immuno-Biological LaboratoriesFY Mar 2026 ¥1.0B
51 OncoTherapy ScienceFY Mar 2026 ¥0.8B
… 17 companies

Workforce information

Source: Annual Securities Report (Jan 2025 to Dec 2025)Parent-onlyDisclosed

86 Employees (parent only) Industry median 94

56.6 Average age Industry median 44.3

6.2 years Average length of service Industry median 9.6 years

¥13.76 million Average annual salary Industry median ¥8.24 million

People and organisation

14.4¥ million Sales per employee Industry median 38.4¥ million FY ending 12/2025 · consolidated / calculated

¥-48.80 million Operating income per employee

79.0% Wage gap between men and women

28.0% Women in managerial positions

3 Average temporary staff

Administrative filings and published information

Workplace information filings

Filed 2023-12-05Disclosed

Item	Value
Employees	150

Audit and disclosure information

Annual securities report, year ended 2025-12-31Disclosed

Item	Value
Audit firm	EY新日本有限責任監査法人
Audit fees (this year, total)	¥41.66 million
Non-audit fees (this year, total)	Not applicable
Non-audit fees (this year, network firms)	¥0.23 million
Going concern note	Note present
Accounting standard	Japanese GAAP

See the book series →

Sources and methodology

Retrieved disclosed figures

Accounts and values from the annual securities report, by section

Major management indicators (5 years) (23 items)

Item	Value	Consolidated / Non-consolidated
Comprehensive income	¥-4.8 billion	Consolidated
Net cash provided by (used in) operating activities	¥-4.6 billion	Consolidated
Net sales	¥1.3 billion	Consolidated
Net cash provided by (used in) investing activities	¥-75.92 million	Consolidated
Cash and cash equivalents	¥2.9 billion	Consolidated
Net assets	¥1.3 billion	Consolidated
Ordinary income (loss)	¥-4.6 billion	Consolidated
Total assets	¥3.9 billion	Consolidated
Equity-to-asset ratio	23.9%	Consolidated
Net income (loss) attributable to owners of parent	¥-4.8 billion	Consolidated
Net cash provided by (used in) financing activities	¥3.6 billion	Consolidated
Basic earnings (loss) per share	-95.12 yen	Consolidated
Net assets per share	15.54 yen	Consolidated
Net sales	¥1.3 billion	Parent only
Net income (loss)	¥-4.9 billion	Parent only
Total number of issued shares (common stock)	59,567,080 shares	Parent only
Net assets	¥1.0 billion	Parent only
Ordinary income (loss)	¥-4.8 billion	Parent only
Total assets	¥3.6 billion	Parent only
Equity-to-asset ratio	19.0%	Parent only
Capital stock	¥19.2 billion	Parent only
Basic earnings (loss) per share	-97.62 yen	Parent only
Net assets per share	11.38 yen	Parent only

Employees (9 items)

Item	Value	Consolidated / Non-consolidated
Number of employees	91 people	Consolidated
Number of employees	91 people	Consolidated
Wage gap between men and women (all employees)	79.0%	Parent only
Average length of service (years)	6.2 years	Parent only
Average annual salary	¥13.76 million	Parent only
Average age (years)	56.6 years old	Parent only
Number of employees	86 people	Parent only
Number of employees	86 people	Parent only
Wage gap between men and women (regular employees)	79.0%	Parent only

Other disclosed items (7 items)

Item	Value	Consolidated / Non-consolidated
Average number of temporary employees	3 people	Consolidated
Average number of temporary employees	3 people	Consolidated
Number of consolidated subsidiaries	1 companies	Consolidated
Average number of temporary employees	3 people	Parent only
Average number of temporary employees	3 people	Parent only
Total return on the share price index	213.2%	Parent only
Ratio of female employees in managerial positions	28.0%	Parent only

Shares (8 items)

Item	Value	Consolidated / Non-consolidated
Number of shares held	8,007,080 shares	Consolidated
Total number of shares held treasury shares etc	91,000 shares	Consolidated
Number of shares	59,567,080 shares	Consolidated
Shareholding ratio treasury shares etc	0.1%	Consolidated
Shareholding ratio	13.5%	Consolidated
Number of shares held in own name treasury shares etc	91,000 shares	Consolidated
Number of voting rights	591,409 units	Consolidated
Total shareholder return	23.7%	Parent only

Research and development (2 items)

Item	Value	Consolidated / Non-consolidated
Research and development expenses included in general and administrative expenses and manufacturing cost for current period	¥3.3 billion	Consolidated
Research and development expenses	¥3.3 billion	Consolidated

Audit (4 items)

Item	Value	Consolidated / Non-consolidated
Fees for audit and attestation services - reporting company	¥41.66 million	Consolidated
Fees for audit and attestation services - total	¥41.66 million	Consolidated
Fees for non-audit services - total	¥0.23 million	Consolidated
Non audit fees consolidated subsidiaries network firms	¥0.23 million	Consolidated

Balance sheet (74 items)

Item	Value	Consolidated / Non-consolidated
Other	¥21.05 million	Consolidated
Other	¥71.68 million	Consolidated
Retained earnings	¥-37.5 billion	Consolidated
Prepaid expenses	¥60.28 million	Consolidated
Advance payments trade	¥0.3 billion	Consolidated
Merchandise and finished goods	¥0.2 billion	Consolidated
Non-current liabilities	¥1.3 billion	Consolidated
Non-current assets	¥43.27 million	Consolidated
Accounts receivable - trade	¥0.3 billion	Consolidated
Tools, furniture and fixtures	¥81.35 million	Consolidated
Buildings	¥0.2 billion	Consolidated
Investments and other assets	¥43.27 million	Consolidated
Lease and guarantee deposits	¥37.35 million	Consolidated
Subscription rights to shares	¥0.3 billion	Consolidated
Income taxes payable	¥0.1 billion	Consolidated
Accounts payable - other	¥0.5 billion	Consolidated
Shareholders' equity	¥0.9 billion	Consolidated
Current liabilities	¥1.3 billion	Consolidated
Current assets	¥3.8 billion	Consolidated
Accumulated depreciation	¥-81.35 million	Consolidated
Accumulated depreciation	¥-0.2 billion	Consolidated
Foreign currency translation adjustment	¥12.93 million	Consolidated
Cash and cash equivalents	¥2.9 billion	Consolidated
Cash and deposits	¥2.9 billion	Consolidated
Net assets	¥1.3 billion	Consolidated
Net assets	¥1.3 billion	Consolidated
Total assets	¥3.9 billion	Consolidated
Deferred tax assets	¥5.90 million	Consolidated
Treasury stock	¥-89.87 million	Consolidated
Valuation and translation adjustments	¥12.93 million	Consolidated
Liabilities	¥2.6 billion	Consolidated
Liabilities and net assets	¥3.9 billion	Consolidated
Supplies	¥0.1 billion	Consolidated
Capital surplus	¥19.2 billion	Consolidated
Capital stock	¥19.2 billion	Consolidated
Convertible-bond-type bonds with share acquisition rights	¥1.3 billion	Consolidated
Net defined benefit liability	¥4.91 million	Consolidated
Shares of subsidiaries and associates	¥0.01 million	Consolidated
Current portion of bonds payable	¥0.7 billion	Consolidated
Other	¥21.05 million	Parent only
Other	¥51.20 million	Parent only
Other capital surplus	¥4.84 million	Parent only
Retained earnings	¥-37.7 billion	Parent only
Prepaid expenses	¥60.28 million	Parent only
Advance payments trade	¥0.3 billion	Parent only
Merchandise and finished goods	¥0.2 billion	Parent only
Non-current liabilities	¥1.3 billion	Parent only
Non-current assets	¥37.37 million	Parent only
Accounts receivable - trade	¥0.3 billion	Parent only
Investments and other assets	¥37.37 million	Parent only
Lease and guarantee deposits	¥37.35 million	Parent only
Subscription rights to shares	¥0.3 billion	Parent only
Consumption taxes receivable	¥60.84 million	Parent only
Income taxes payable	¥0.1 billion	Parent only
Accounts payable - other	¥0.4 billion	Parent only
Shareholders' equity	¥0.7 billion	Parent only
Current liabilities	¥1.2 billion	Parent only
Current assets	¥3.5 billion	Parent only
Cash and deposits	¥2.5 billion	Parent only
Net assets	¥1.0 billion	Parent only
Net assets	¥1.0 billion	Parent only
Total assets	¥3.6 billion	Parent only
Retained earnings brought forward	¥-37.7 billion	Parent only
Treasury stock	¥-89.87 million	Parent only
Liabilities	¥2.5 billion	Parent only
Liabilities and net assets	¥3.6 billion	Parent only
Supplies	¥0.1 billion	Parent only
Capital surplus	¥19.2 billion	Parent only
Legal capital surplus	¥19.2 billion	Parent only
Capital stock	¥19.2 billion	Parent only
Convertible-bond-type bonds with share acquisition rights	¥1.3 billion	Parent only
Provision for retirement benefits	¥4.91 million	Parent only
Shares of subsidiaries and associates	¥0.01 million	Parent only
Current portion of bonds payable	¥0.7 billion	Parent only

Statement of income (85 items)

Item	Value	Consolidated / Non-consolidated
Other	¥2.14 million	Consolidated
Other	¥1.09 million	Consolidated
Other comprehensive income	¥5.03 million	Consolidated
Comprehensive income	¥-4.8 billion	Consolidated
Insurance	¥24.39 million	Consolidated
Interest income	¥4.20 million	Consolidated
Operating income	¥-4.4 billion	Consolidated
Non-operating income	¥30.73 million	Consolidated
Non-operating expenses	¥0.2 billion	Consolidated
Net cash provided by (used in) operating activities	¥-4.6 billion	Consolidated
Cost of sales	¥0.4 billion	Consolidated
Gross profit (loss)	¥0.9 billion	Consolidated
Net sales	¥1.3 billion	Consolidated
Net income	¥-4.8 billion	Consolidated
Net income	¥-4.8 billion	Consolidated
Net income (loss)	¥-4.8 billion	Consolidated
Net income (loss)	¥-4.8 billion	Consolidated
Directors' compensations	¥0.2 billion	Consolidated
Net cash provided by (used in) investing activities	¥-75.92 million	Consolidated
Commission fees	¥12.34 million	Consolidated
Issuance of new shares	¥1.3 billion	Consolidated
Gain on reversal of share acquisition rights	¥8.54 million	Consolidated
Stock issuance cost	¥10.08 million	Consolidated
Income taxes - current	¥33.21 million	Consolidated
Income taxes	¥27.57 million	Consolidated
Income taxes - deferred	¥-5.64 million	Consolidated
Impairment loss	¥0.1 billion	Consolidated
Foreign exchange losses	¥64.96 million	Consolidated
Foreign currency translation adjustment net of tax	¥5.03 million	Consolidated
Extraordinary income	¥8.54 million	Consolidated
Extraordinary loss	¥0.1 billion	Consolidated
Effect of exchange rate change on cash and cash equivalents	¥-50.20 million	Consolidated
Net increase (decrease) in cash and cash equivalents	¥-1.1 billion	Consolidated
Research and development expenses	¥3.3 billion	Consolidated
Interest on bonds	¥39.17 million	Consolidated
Bond issuance cost	¥0.1 billion	Consolidated
Income (loss) before income taxes	¥-4.7 billion	Consolidated
Income (loss) before income taxes	¥-4.7 billion	Consolidated
Ordinary income	¥-4.6 billion	Consolidated
Payrolls and allowances-SGA	¥0.5 billion	Consolidated
Disposal of treasury stock	¥7,000	Consolidated
Purchase of treasury stock	¥-0.05 million	Consolidated
Comprehensive income attributable to owners of parent	¥-4.8 billion	Consolidated
Net cash provided by (used in) financing activities	¥3.6 billion	Consolidated
Promotion expenses	¥0.5 billion	Consolidated
Selling, general and administrative expenses	¥5.4 billion	Consolidated
Retirement benefit expenses	¥0.64 million	Consolidated
Other	¥2.14 million	Parent only
Other	¥1.09 million	Parent only
Insurance	¥24.39 million	Parent only
Interest income	¥4.20 million	Parent only
Total	¥0.5 billion	Parent only
Ending merchandise and finished goods	¥0.2 billion	Parent only
Beginning merchandise and finished goods	¥0.2 billion	Parent only
Operating income	¥-4.6 billion	Parent only
Non-operating income	¥30.73 million	Parent only
Non-operating expenses	¥0.2 billion	Parent only
Cost of sales	¥0.4 billion	Parent only
Gross profit (loss)	¥0.9 billion	Parent only
Net sales	¥1.3 billion	Parent only
Net income (loss)	¥-4.9 billion	Parent only
Net income (loss)	¥-4.9 billion	Parent only
Directors' compensations	¥0.2 billion	Parent only
Fee expenses	¥60.50 million	Parent only
Commission fees	¥12.34 million	Parent only
Issuance of new shares	¥1.3 billion	Parent only
Gain on reversal of share acquisition rights	¥8.54 million	Parent only
Stock issuance cost	¥10.08 million	Parent only
Income taxes - current	¥3.80 million	Parent only
Income taxes	¥3.80 million	Parent only
Impairment loss	¥0.1 billion	Parent only
Foreign exchange losses	¥74.13 million	Parent only
Extraordinary income	¥8.54 million	Parent only
Extraordinary loss	¥0.1 billion	Parent only
Research and development expenses	¥3.4 billion	Parent only
Interest on bonds	¥39.17 million	Parent only
Bond issuance cost	¥0.1 billion	Parent only
Income (loss) before income taxes	¥-4.9 billion	Parent only
Ordinary income	¥-4.8 billion	Parent only
Payrolls and allowances-SGA	¥0.5 billion	Parent only
Disposal of treasury stock	¥7,000	Parent only
Purchase of treasury stock	¥-0.05 million	Parent only
Promotion expenses	¥0.5 billion	Parent only
Selling, general and administrative expenses	¥5.5 billion	Parent only
Retirement benefit expenses	¥0.57 million	Parent only

Accounts unique to this company (4 items)

Item	Value	Consolidated / Non-consolidated
Revenue	¥0.5 billion	Consolidated
Revenue	¥-10.37 million	Consolidated
Revenue	¥0.3 billion	Parent only
Revenue	¥0.5 billion	Parent only

Statement of changes in equity (4 items)

Item	Value	Consolidated / Non-consolidated
Total changes during the period	¥-2.9 billion	Consolidated
Net changes in items other than shareholders' equity	¥36.14 million	Consolidated
Total changes during the period	¥-3.1 billion	Parent only
Net changes in items other than shareholders' equity	¥31.11 million	Parent only

Statement of cash flows (35 items)

Item	Value	Consolidated / Non-consolidated
Other	¥0.25 million	Consolidated
Increase (decrease) in other current liabilities	¥0.24 million	Consolidated
Decrease (increase) in other current assets	¥-0.1 billion	Consolidated
Proceeds from insurance income	¥24.39 million	Consolidated
Interest expenses paid	¥-39.24 million	Consolidated
Interest and dividends income received	¥4.20 million	Consolidated
Decrease (increase) in prepaid expenses	¥23.70 million	Consolidated
Insurance	¥-24.39 million	Consolidated
Interest income	¥-4.20 million	Consolidated
Decrease increase in notes and accounts receivable trade	¥0.2 billion	Consolidated
Purchase of shares of subsidiaries	¥-0.01 million	Consolidated
Subtotal	¥-4.5 billion	Consolidated
Commission fees	¥12.34 million	Consolidated
Proceeds from collection of lease and guarantee deposits	¥6.57 million	Consolidated
Proceeds from issuance of subscription rights to shares	¥3.30 million	Consolidated
Proceeds from exercise of share acquisition rights	¥1.3 billion	Consolidated
Proceeds from issuance of bonds with subscription rights to shares	¥1.7 billion	Consolidated
Gain on reversal of share acquisition rights	¥-8.54 million	Consolidated
Decrease/increase in consumption taxes receivable/payable	¥-27.65 million	Consolidated
Increase (decrease) in accounts payable-other	¥-0.2 billion	Consolidated
Payments for issuance of common stock	¥-10.08 million	Consolidated
Stock issuance cost	¥10.08 million	Consolidated
Share-based payment expenses	¥94.71 million	Consolidated
Decrease (increase) in inventories	¥-50.03 million	Consolidated
Income taxes refund (paid)	¥-12.60 million	Consolidated
Impairment loss	¥0.1 billion	Consolidated
Foreign exchange loss (gain)	¥55.09 million	Consolidated
Purchase of intangible assets	¥-82.47 million	Consolidated
Redemption of bonds	¥-0.6 billion	Consolidated
Proceeds from issuance of bonds	¥1.2 billion	Consolidated
Interest on bonds	¥39.17 million	Consolidated
Bond issuance cost	¥0.1 billion	Consolidated
Proceeds from disposition of treasury stock	¥7,000	Consolidated
Regarding purchase of treasury stock	¥-0.05 million	Consolidated
Increase (decrease) in net defined benefit liability	¥0.31 million	Consolidated

Basic indicators

Item	Value	Consolidated / Non-consolidated	Source
Net cash provided by (used in) operating activities	¥-4.6 billion	Consolidated	Disclosed
Number of employees	91	Consolidated	Disclosed
Net assets	¥1.3 billion	Consolidated	Disclosed
Net sales	¥1.3 billion	Consolidated	Disclosed
Operating income	¥-4.4 billion	Consolidated	Disclosed
Ordinary income	¥-4.6 billion	Consolidated	Disclosed
Net income	¥-4.8 billion	Consolidated	Disclosed
Total assets	¥3.9 billion	Consolidated	Disclosed
Operating margin	-339.6%	Consolidated	Calculated
Net margin	-365.3%	Consolidated	Calculated
Sales per employee	14369758 yen	Consolidated	Calculated
Total asset turnover	0.34 times	Consolidated	Calculated
Net assets to total assets	32.9%	Consolidated	Calculated

How to read the figures, and caveats

Terms

Consolidated: the parent company together with the subsidiaries it consolidates
Parent-only: the single company that filed the annual securities report
Calculated: a disclosed figure put through the formula shown
Not disclosed: no such value in the filing (not treated as zero)
Not retrieved: a value this page could not extract, including values in the filing that could not be matched. The same item may appear in another table
Segment: a business division the company uses in its disclosures
Industry median: the middle value among companies in the same industry that disclose the item
★: position when every company is lined up by value (not a judgement of the company)See the formulas
Source: document name, period covered, filing date and where it was obtained
Tables scroll sideways

Key figures

Operating margin -339.6%　Operating income ÷ net sales 　＝ ¥-4.4 billion ÷ ¥1.3 billion
Operating income ÷ net sales. The denominator is Net sales (Consolidated, Japanese GAAP).
Net margin -365.3%　Net income ÷ net sales 　＝ ¥-4.8 billion ÷ ¥1.3 billion
Net income ÷ net sales. The denominator is Net sales (Consolidated, Japanese GAAP).
Sales per employee 14,369,758 yen　Sales or operating revenue ÷ employees 　＝ ¥1.3 billion ÷ 91 people
Sales or operating revenue ÷ employees. The denominator is Number of employees (Consolidated, Japanese GAAP).
Total asset turnover 0.34 times　Sales or operating revenue ÷ total assets 　＝ ¥1.3 billion ÷ ¥3.9 billion
Sales or operating revenue ÷ total assets. The denominator is Total assets (Consolidated, Japanese GAAP).
Net assets to total assets 32.9%　Net assets ÷ total assets 　＝ ¥1.3 billion ÷ ¥3.9 billion
Net assets ÷ total assets. The denominator is Total assets (Consolidated, Japanese GAAP).

Company details

Representative　代表取締役社長兼CEO, gBizINFO
Consolidated subsidiaries　Annual Securities Report

Business activities and revenue composition

Breakdown by business: machine transcription of segment information (business divisions used in disclosures) in the annual securities report. No table where segment sales differ from the disclosed total by more than 1%, or where the company reports a single business

Amounts by account

Totals and their component lines together; consolidated and parent-only figures mixed (right-hand column)

Selling, general and administrative expenses

Breakdown of selling, general and administrative expenses (costs of selling and running the company). Cost of sales not included
Each item: already inside the SG&A total (not added to it)

Finance

Net assets to total assets　Net assets ÷ total assets
Return on assets (ROA)　Net income ÷ total assets (consolidated)
Net assets per share　Consolidated
Free cash flow　Free cash flow: operating cash flow (cash generated by the business) plus investing cash flow (asset purchases, disposals and other investments), consolidated
Total assets　Consolidated

Capital allocation

★: position when all companies are sorted by value and cut into fifths (a position, not a rating). The five items with ★: only where both numerator and denominator are available on a consolidated basisSee the formulas
Increase in working capital　(increase in trade receivables + increase in inventories) ÷ net sales (or operating revenue)。Trade receivables down ¥0.2 billion + inventories up ¥50.03 million, over net sales ¥1.3 billion

Long-term changes in performance

Revenue　Disclosed value for 2025 ÷ disclosed value for 2012

Year-on-year comparison

Year on year: calculated only where the item, reporting range and accounting standard match and the periods are consecutive
Comparison basis not confirmed: periods with a change of accounting standard or reporting range, a moved fiscal year end, or an unconfirmed period
◆: a period where revenue moved 20% or more from the prior year, profit as a share of revenue moved 2.0 percentage points or more, or profit or loss changed sign. Item used named in the table and list. Not a ranking of companies

Earnings and net assets per share over time

Earnings per share = net profit ÷ shares; net assets per share = net assets ÷ shares. Disclosed values from the key financial indicators of the annual securities report. No share prices used

Share ownership by holder category

Source: ownership table, annual securities report. Percentages as disclosed, calculated on trading units (some companies do not total exactly 100%). Foreign holders (total): institutions and individuals combined. “Individuals and others”: a register category (not necessarily the share actually held by individuals). Industry median: the middle value among companies in Pharmaceuticals that disclose the item (industries with at least 5 companies only).

Major shareholders

Source: major shareholders table, annual securities report. Trust bank holdings as written (whose trust is not disclosed)

Research and development expenses and capital expenditure

Research and development: total in the R&D section of the annual securities report. Capital expenditure: this year’s actual spending in the capital expenditure overview (not a plan). Years: only those available in the annual securities reports on hand (one to four per company); no row for other years. Share of revenue: divided by consolidated revenue in the same annual securities report. Industry median: the middle value among companies in Pharmaceuticals that disclose the item (industries with at least 5 companies only).

Revenue scale in the same industry

Revenue (disclosed values) of companies in the same industry, using the same grouping as the industry pages. Only the top three and the two companies either side of this one. Bar length relative to the largest company (100). An order of size, not a ranking of quality

Workforce information

All four: the reporting company (parent-only), as disclosed in the employee section of the annual securities report. Employees across the consolidated group: 91 (a different scope, kept apart from the four above). Industry median: the middle value among companies in Pharmaceuticals that disclose the item (industries with at least 5 companies only).

People and organisation

Sales per employee　Net sales (or operating revenue) ÷ employees
Operating income per employee　Operating income ÷ employees
Wage gap between men and women　Women's pay with men's pay set to 100, reporting company
Women in managerial positions　Reporting company (parent only)
Average temporary staff　Consolidated, average headcount other than regular employees

Workplace information filings

Source: processed from Shokuba-labo, the workplace information site of the Ministry of Health, Labour and Welfare. Items the company filed only Shokuba-labo

Audit and disclosure information

Whether there is a going concern note (the accounting assumption that a company will continue operating), and audit information
Audit firm, audit fees, going concern note and accounting standard: facts written in the latest annual securities report and the audit report filed with it (not a judgement of the company). Going concern note: “note” when the note text is present, “not applicable” when the report states nothing to report, “cannot be determined” when neither appears. Note text not reproduced. Amended filings not shown (annual securities reports only)

Data sources and calculation methods

Primary source: the annual securities report of SymBio Pharmaceuticals Limited on EDINET, the FSA’s disclosure system (free to read)
Corporate number: 1010401057034 / Accounting standard: Japanese GAAP

Amounts: machine transcription of EDINET XBRL (no manual re-keying). Long narrative notes are text and not in the account list. Identifiers: machine transcription of the EDINET code list (retrieved 2026-08-22)
★: position of the value calculated from disclosed figures among the 4,240 companies on this site, on a five-step scale. Not a judgement of the company. No forecasts usedThe formulas and how they are counted
No rank: net assets as a share of total assets, cash conversion and revenue per employee (size alone does not show quality). Industry median shown for comparison. Cash conversion of 100%: operating cash flow equal to operating profit
Profit-and-loss chart: only where “sales − cost of sales − SG&A = operating income” holds between disclosed values. Cost breakdown: the six largest SG&A items
Trend charts: key financial indicators of the annual securities report. Amounts in billions of yen (dividend per share in yen). Long-run chart joins reports filed in different years (newer report for overlapping years). Some items stop part-way after a change of accounting standard. A stock split changes the weight of one share. Consolidated and parent-only in separate tables
Revenue scale in the same industry: bars of revenue (disclosed values) of companies in the same industry grouping as the industry pages, largest first. Only the top three and the two companies either side of this one. Each company’s latest fiscal year. An order of size, not a ranking of quality or an investment view
Share prices: not published (no data source allows redistribution). No share-price-based indicators (such as the price earnings ratio) and no extension of past growth into the future
Average age, average length of service and average annual salary: the reporting company alone (the parent). At a holding company, a small head-office staff. Payout ratio (basic facts): dividend per share ÷ consolidated earnings per share, calculated here (the payout ratio in the annual securities report is the reporting company’s figure, on a different basis). Representative and founding date: gBizINFO (Ministry of Economy, Trade and Industry), some companies only
“Retrieved disclosed figures”: every value readable as a number from the annual securities report. Company-wide values only (no segment or other breakdowns)
Segment table: machine transcription of the segment information in the annual securities report. Business names as labelled by the company in its XBRL. No table where segment sales differ from the disclosed total by more than 1%. Adjustments, corporate, eliminations and “other” left out of the table and the share denominator, as they are not businesses
Breakdowns of amounts, not diagrams of how the business works. Who pays whom, and for what, is not in the disclosed figures; no lines drawn from guesswork

SymBio Pharmaceuticals

Company highlights

Key figures

Company profile

Disclosed data

Business activities and revenue composition

Revenue and profit

Selling, general and administrative expenses

Performance, financial position and capital allocation

Long-term changes in performance

Long-term revenue, profit and asset trends

Recent performance trends

Year-on-year comparison

Fiscal periods marked for changes

Earnings and net assets per share over time

Shareholder composition

Share ownership by holder category

Major shareholders

Research and development expenses and capital expenditure

Revenue scale in the same industry

Workforce information

Administrative filings and published information

Workplace information filings

Audit and disclosure information

Related books, articles and videos

Sources and methodology

Terms

Key figures

Company details

Business activities and revenue composition

Amounts by account

Selling, general and administrative expenses

Finance

Capital allocation

Long-term changes in performance

Year-on-year comparison

Earnings and net assets per share over time

Share ownership by holder category

Major shareholders

Research and development expenses and capital expenditure

Revenue scale in the same industry

Workforce information

People and organisation

Workplace information filings

Audit and disclosure information

Data sources and calculation methods